KOD · Kodiak Sciences Inc. · Webcasts, Transcripts & Audio
$94.57
+0.12 (+0.12%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026, we had cash and cash equivalents of $125.9 million. We have incurred net losses and negative cash flows from operations since inception. We expect to continue to incur operating losses and negative operating cash flows for the foreseeable future and as a result, there is substantial doubt regarding our ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$2.03B
Shares
62.85M
Volume · Oct 5
2.2M
Avg daily vol (3M)
1.5M
Kodiak Sciences Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Kodiak Sciences Inc. (KOD), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Earnings call
FY26 · Q2
2026-09-28
Kodiak Sciences Inc. (KOD) Q2 2026 Earnings Call
Diluted EPS
$-1.05
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-04
Kodiak Sciences Inc. (KOD) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-01-12
Kodiak Sciences Inc. (KOD) January 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q3
2025-12-04
Kodiak Sciences Inc. (KOD) Q3 2025 Earnings Call
Diluted EPS
$-1.16
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-09-05
Kodiak Sciences Inc. (KOD) Q2 2025 Earnings Call
Diluted EPS
$-1.03
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-27
Kodiak Sciences Inc. (KOD) Q4 2024 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Kodiak Sciences Inc. (KOD) Q3 2024 Earnings Call
Diluted EPS
$-0.84
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-28
Kodiak Sciences Inc. (KOD) Q4 2023 Earnings Call Transcript
Positive tone
Tarcocimab Phase 3 program and GLOW2 / DAYBREAK
KSI-501 enhanced formulation and wet AMD pivotal
Uncertainty around second KSI-501 pivotal study timing
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q1
2020-05-11
Kodiak Sciences Inc. (KOD) Q1 2020 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Showing 1–9 of 9 webcasts